Overview

A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Participants

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of moderate and severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in adult cancer participants. This study will also evaluate the safety and tolerability of intravenous/subcutaneous azacitidine in adult cancer participants.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Azacitidine
Cc-486